Avalo Therapeutics (AVTX) Total Current Liabilities (2014 - 2026)
Avalo Therapeutics posted quarterly Total Current Liabilities of $11.6 million for Q1 2026, up 106.57% year-on-year from $5.6 million in Q1 2025, and down 10.36% on a QoQ basis from $12.9 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Total Current Liabilities data on file, last reported at $11.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 106.57% year-over-year to $11.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (up 106.57% YoY), and the FY2025 full-year result was $12.9 million, up 85.92% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $11.6 million, down from $12.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $215.7 million in Q1 2024 and bottomed at $4.6 million in Q4 2023.
- The 5-year median for Total Current Liabilities is $15.4 million (2022), against an average of $32.8 million.
- The widest annual swing landed in 2024, when Total Current Liabilities jumped 910.39%; it then sank 97.4% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $22.1 million in 2022, then sank by 79.12% to $4.6 million in 2023, then soared by 50.71% to $7.0 million in 2024, then jumped by 85.92% to $12.9 million in 2025, then decreased by 10.36% to $11.6 million in 2026.
- The last three Total Current Liabilities figures came in at $11.6 million (Q1 2026), $12.9 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 11.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.60 Mn |
| Dec 31, 2025 | 12.94 Mn |
| Sep 30, 2025 | 7.97 Mn |
| Jun 30, 2025 | 9.26 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 6.96 Mn |
| Sep 30, 2024 | 60.67 Mn |
| Jun 30, 2024 | 96.40 Mn |
| Mar 31, 2024 | 215.70 Mn |
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 6.01 Mn |
| Jun 30, 2023 | 22.45 Mn |
| Mar 31, 2023 | 23.25 Mn |
| Dec 31, 2022 | 22.11 Mn |
| Sep 30, 2022 | 18.15 Mn |
| Jun 30, 2022 | 15.40 Mn |
| Mar 31, 2022 | 17.89 Mn |
| Dec 31, 2021 | 19.89 Mn |
| Sep 30, 2021 | 19.04 Mn |
| Jun 30, 2021 | 21.67 Mn |
| Mar 31, 2021 | 26.36 Mn |
| Dec 31, 2020 | 15.23 Mn |
| Sep 30, 2020 | 16.57 Mn |
| Jun 30, 2020 | 14.60 Mn |
| Mar 31, 2020 | 15.33 Mn |
| Dec 31, 2019 | 12.16 Mn |
| Sep 30, 2019 | 17.26 Mn |
| Jun 30, 2019 | 18.77 Mn |
| Mar 31, 2019 | 28.13 Mn |
| Dec 31, 2018 | 26.22 Mn |
| Sep 30, 2018 | 24.91 Mn |
| Jun 30, 2018 | 19.05 Mn |
| Mar 31, 2018 | 14.79 Mn |
| Dec 31, 2017 | 11.09 Mn |
| Sep 30, 2017 | 4.83 Mn |
| Jun 30, 2017 | 1.66 Mn |
| Mar 31, 2017 | 2.74 Mn |
| Dec 31, 2016 | 4.31 Mn |
| Sep 30, 2016 | 7.50 Mn |
| Jun 30, 2016 | 6.59 Mn |
| Mar 31, 2016 | 6.17 Mn |
| Dec 31, 2015 | 5.85 Mn |
| Sep 30, 2015 | 6.65 Mn |
| Dec 31, 2014 | 4.99 Mn |